Categories Markets, Retail

Goldman downgrade is a call for Walgreens to revisit biz strategy

Shares of pharmacy store chain Walgreens Boots Alliance Inc. (WBA) dropped sharply Friday after they were downgraded by Goldman Sachs, in what could be an alert against the growing presence of online players like Amazon (AMZN) in the pharma retail space. The price target on the stock was lowered to $68, significantly below Friday’s opening price.

Citing the challenges facing the retail pharmacy business, the research firm cut its rating on Walgreens to sell from neutral. The stock has been on a downward spiral after hitting a three-year high earlier this month. It gained about 10% since the beginning of the year.

Citing the challenges facing the retail pharmacy business, the research firm cut its rating on Walgreens to sell from neutral

Analysts are of the view that the management’s present strategy, marked by business partnerships across multiple sectors, is inadequate to sustain growth. Most of the company’s tie-ups are structured to increase footfall in its stores, which according to the analysts is an ineffective method to counter the growing threat from online drug retailers.

The new rating – the only sell tag on the company currently – could be a dampener as far as investors are concerned. The majority of other market watchers recommends either buy or hold for Walgreens.

The downgrade comes in the midst of hectic merger activity in the sector, which recently witnessed Walgreens’ arch-rival CVS Health (CVS) acquiring Aetna (AET), a leading health insurance firm, and Amazon boosting its online drug delivery service by adding PillPack into its fold.

Walgreens Q4 earnings beat; stock tanks on sales miss

Soon after each of the high-value deals involving online retailers, investor sentiment turned bearish causing the stocks of pharma store operators to fall sharply. For Walgreens, the chances of retaining the growth momentum through acquisitions are bleak due to its high debt and unimpressive cash flow.

Adding to the woes of conventional store operators, President Donald Trump recently raised concerns about the high costs of pharmaceutical products including medicine, forcing several companies to slash their prices.

 

Listen to publicly listed companies’ earnings conference calls along with the edited closed caption text

Most Popular

Does Unity Software (U) stock has more room to run?

Last month, the IPO market was in a full swing. IPOs of Snowflake (NYSE: SNOW) and JFROG (NASDAQ: FROG) had an impressive opening day in September, the former creating a

PepsiCo (PEP): Steady snacking habits amid pandemic drive strong quarter for beverage giant

PepsiCo Inc. (NASDAQ: PEP) beat market expectations on both revenue and earnings for the third quarter of 2020. The company saw the momentum continue in its snacks business while the

Does the virus-driven boom make Electronic Arts (EA) a good investment?

With more and more people turning to virtual entertainment sources, amid the virus-related movement restrictions, video game publishers like Electronic Arts (NASDAQ: EA) are witnessing unusually high demand. Not surprisingly,

Leave a Reply

Your email address will not be published. Required fields are marked *

Add Comment
Loading...

Cancel
Viewing Highlight
Loading...
Highlight
Close
Top